<DOC>
	<DOCNO>NCT00165802</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) E7974 bolus IV administration , Day 1 21-day cycle , patient advance solid tumor progress follow effective therapy effective therapy exists .</brief_summary>
	<brief_title>A Phase I Open Label Study E7974 Administered Day 1 21-Day Cycle In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The MTD Day 1 21-Day schedule define 0.45 mg/m2 dose level . The study terminate prior full enrollment colorectal cancer ( CRC ) expansion cohort , due lack demonstrate activity result Principal Investigator ( PI ) loss interest continue enrollment . Collection outstanding data ongoing database lock estimate complete June 2008 .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>At time , enrol patient MTD cohort meet study entry criterion , plus CRC criterion ( Inclusion Criterion # 12 ) .Patients meet inclusion criterion none exclusion criterion eligible entry study . Patients must : 1 . Have histologically cytologically confirm advanced solid tumor progress follow effective therapy effective therapy exists ( include surgery radiation therapy ) . 2 . Be &gt; = 18 year age . 3 . Have Eastern Cooperative Oncology Group ( ECOG ) status 0 , 1 , 2 . 4 . Have life expectancy &gt; = 3 month . 5 . Have adequate renal function evidence serum creatinine &lt; = 1.5 mg/dL creatinine clearance &gt; = 40 mL/minute . 6 . Have adequate bone marrow function evidence absolute neutrophil count &gt; = 1,500/µL , hemoglobin &gt; = 9 g/dL ( may transfuse ) , platelet count ( transfuse ) &gt; = 100,000/µL . 7 . Have adequate liver function evidence bilirubin &lt; = 1.5 x ULN alanine transaminase ( ALT ) aspartate transaminase ( AST ) &lt; = 3 time upper limit normal ( ULN ) , unless relate liver involvement tumor , case &lt; = 5.0 x ULN . 8 . Give write informed consent . 9 . Be willing able comply study protocol duration study . 10 . Be willing undergo blood draw urine sample PK Cycle 1 . 11 . Can either measurable nonmeasurable disease . 12 . If CRC patient treat MTD , must &lt; = 4 prior regimen metastatic setting . The presence one follow criterion disqualify patient enrollment study : 1 . Patients receive chemotherapy within 3 week E7974 treatment start ; ( six week nitrosoureas ) . 2 . Patients recover chemotherapyrelated therapyrelated toxicity &lt; Grade 1 study entry ( exclude alopecia Grade 2 ) . 3 . Patients receive radiotherapy &lt; = 3 week prior study enrollment , ( prior radiation therapy allow &lt; 25 % bone marrow ) , recover toxic effect treatment prior study enrollment ( except alopecia ) . Lesions radiate included site measurable disease unless clear tumor progression document lesion since end radiation therapy . 4 . Patients major surgery without full recovery major surgery within three week E7974 treatment start . 5 . Patients primary brain tumor metastasis study entry must control &gt; one month previous treatment , include radiation therapy /or corticosteroid . 6 . Women pregnant breastfeeding . 7 . Women childbearing potential either positive pregnancy test screening pregnancy test . 8 . Women childbearing potential unless ( 1 ) surgically sterile ( 2 ) physiologically postmenopausal &gt; 12 month , ( 3 ) use adequate measure ( include barrier method ) contraception . 9 . Fertile men partner willing use contraception . 10 . Patients history positive test Human Immunodeficiency Virus ( HIV ) and/or active hepatitis B active hepatitis C study entry . 11 . Patients severe , uncontrolled intercurrent illness infection . 12 . Patients medically uncontrolled cardiovascular illness define unstable angina congestive heart failure ( CHF ) , &gt; symptomatic Grade II New York Heart Association ( NYHA ) Classification , myocardial infarction ( MI ) within six month prior study entry . 13 . Patients receive organ allograft require immunosuppressive therapy . 14 . Patients receive investigational drug include immunotherapy , gene therapy , hormone therapy , biologic therapy , chemotherapy within threeweek period prior E7974 treatment start ; patient must recover previous major therapy relate toxicity ( Grade 3 4 ) &lt; = Grade 1 study entry . 15 . Patients current history peripheral neuropathy &gt; CTC Grade 2 ( e.g. , diabetic chemotherapyinduced neuropathy ) . 16 . Patients history uncontrolled seizure . 17 . Patients significant disease disorder , investigator 's opinion , would exclude study . 18 . Patients mark screen baseline prolongation QT/QTc interval ( QTc interval &gt; 470 mm ) use Fridericia method main method QTc analysis . 19 . Patients allergy hypersensitivity hemiasterlin base product analogue .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Cancer</keyword>
	<keyword>malignant tumor</keyword>
</DOC>